	US 12,188,946 B2
	Biomarkers for diagnosing tuberculous meningitis
Novel Njweipi Chegou, Bellville (ZA); Regan Shane Solomons, Kuils River (ZA); Gerhard Walzl, Cape Town (ZA); and Masilo Charles Manyelo, Parow Valley (ZA)
Assigned to STELLENBOSCH UNIVERSITY, Stellenbosch (ZA)
Appl. No. 17/057,628
Filed by STELLENBOSCH UNIVERSITY, Stellenbosch (ZA)
PCT Filed May 23, 2019, PCT No. PCT/IB2019/054259 § 371(c)(1), (2) Date Nov. 20, 2020, PCT Pub. No. WO2019/224755, PCT Pub. Date Nov. 28, 2019.
Claims priority of application No. 2018/03410 (ZA), filed on May 23, 2018.
Prior Publication US 2021/0199668 A1, Jul. 1, 2021
Int. Cl. C12Q 1/70 (2006.01); G01N 33/68 (2006.01); A61B 5/15 (2006.01); A61B 10/00 (2006.01); G01N 21/64 (2006.01)

CPC G01N 33/6863 (2013.01) [A61B 5/15 (2013.01); A61B 2010/0077 (2013.01); A61B 2503/06 (2013.01); G01N 2021/6439 (2013.01); G01N 2333/35 (2013.01)]

8 Claims

1. A method for diagnosing and treating a subject with tuberculous meningitis (TBM), the method comprising the steps of:

testing a cerebrospinal fluid (CSF) sample from a subject suspected of having TBM for the presence of MPO, IFN-γ and at least one other biomarker selected from the group consisting of SICAM-1, VEGF-A and CXCL8;

determining that the subject has TBM based on the detection of the biomarkers in the sample; and

administering an effective amount of TBM treatment to the subject.